• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Two European firms ally in PET

Article

Alliance Medical of Oxfordshire and M2i of Dublin have formed a joint venture to produce and distribute PET radiopharmaceuticals in the U.K. The new company, called Molecular Imaging Services, will focus on the production of F-18 FDG (fluorodeoxyglucose)

Alliance Medical of Oxfordshire and M2i of Dublin have formed a joint venture to produce and distribute PET radiopharmaceuticals in the U.K. The new company, called Molecular Imaging Services, will focus on the production of F-18 FDG (fluorodeoxyglucose) through a series of dedicated radiopharmaceutical production units. These units will serve both hospital-based PET facilities and mobile PET scanners. Alliance Medical operates two PET scanners in the U.K.: a stationary unit at a facility located in London and a mobile PET scanner serving three hospitals. The mobile PET will soon begin serving a fourth hospital.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.